FPS
RARE icon

Fieldpoint Private Securities’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fieldpoint Private Securities’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$11K – 535
2017
Q3 		$11K Buy
+200
New +$11.8K ﹤0.01% 582
2017
Q2 		– Sell
-240
Closed -$16K – 293
2017
Q1 		$16K Buy
+240
New +$18.3K 0.01% 283

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fieldpoint Private Securities's RARE Position: Q4 2017 in Review

Fieldpoint Private Securities sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2017, closing a stake of 200 shares — an estimated $11K sold.

Fieldpoint Private Securities first reported a position in RARE in Q1 2017 and held it in 2 quarters. The position peaked at $16K in Q1 2017. 163 funds tracked by Wall St. Rank hold RARE as of Q4 2017.

  • Fieldpoint Private Securities reported no remaining Ultragenyx Pharmaceutical position as of Q4 2017 after selling out during the quarter.
  • Fieldpoint Private Securities sold 200 Ultragenyx Pharmaceutical shares in Q4 2017, an estimated $11K.
  • Fieldpoint Private Securities first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and held it in 2 quarters.
  • Fieldpoint Private Securities's Ultragenyx Pharmaceutical position peaked at $16K in Q1 2017.
  • 163 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2017.

Based on Fieldpoint Private Securities's 13F filing for Q4 2017, filed 15 Feb 2018.